Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK

Rong Huang, Hyunju Oh, Allison Arrendale, Victoria A. Martin, Jacob Galan, Eric J. Workman, Jane R. Stout, Claire Walczak, W. Andy Tao, Richard F. Borch, Robert L. Geahlen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

SH2 domains are attractive targets for chemotherapeutic agents due to their involvement in the formation of protein-protein interactions critical to many signal transduction cascades. Little is known, however, about how synthetic SH2 domain ligands would influence the growth properties of tumor cells or with which intracellular proteins they would interact due to their highly charged nature and enzymatic lability. In this study, a prodrug delivery strategy was used to introduce an enzymatically stable, phosphotyrosine peptidomimetic into tumor cells. When tested in a human tumor cell panel, the prodrug exhibited a preference for inhibiting the growth of leukemia and lymphoma cells. In these cells, it was largely cytostatic and induced endoreduplication and the appearance of midbodies. Proteomic analyses identified multiple targets that included mitotic centromere-associated kinesin (MCAK). Molecular modeling studies suggested the ATP-binding site on MCAK as the likely site of drug interaction. Consistent with this, ATP inhibited the drug-MCAK interaction and the drug inhibited MCAK ATPase activity. Accordingly, the effects of the prodrug on the assembly of the mitotic spindle and alignment of chromosomes were consistent with the identification of MCAK as an important intracellular target.

Original languageEnglish
Pages (from-to)597-611
Number of pages15
JournalBiochemical Pharmacology
Volume86
Issue number5
DOIs
StatePublished - 2013

Fingerprint

Peptidomimetics
Kinesin
Phosphotyrosine
Centromere
Prodrugs
Tumors
src Homology Domains
Cells
Drug Interactions
Adenosine Triphosphate
Endoreduplication
Drug interactions
Neoplasms
Signal transduction
Spindle Apparatus
Proteins
Molecular modeling
Cytostatic Agents
Chromosomes
Growth

Keywords

  • Drug delivery
  • Kinesin
  • MCAK
  • Peptidomimetic
  • SH2 domain
  • Signal transduction

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Huang, R., Oh, H., Arrendale, A., Martin, V. A., Galan, J., Workman, E. J., ... Geahlen, R. L. (2013). Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK. Biochemical Pharmacology, 86(5), 597-611. https://doi.org/10.1016/j.bcp.2013.06.024

Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK. / Huang, Rong; Oh, Hyunju; Arrendale, Allison; Martin, Victoria A.; Galan, Jacob; Workman, Eric J.; Stout, Jane R.; Walczak, Claire; Tao, W. Andy; Borch, Richard F.; Geahlen, Robert L.

In: Biochemical Pharmacology, Vol. 86, No. 5, 2013, p. 597-611.

Research output: Contribution to journalArticle

Huang, R, Oh, H, Arrendale, A, Martin, VA, Galan, J, Workman, EJ, Stout, JR, Walczak, C, Tao, WA, Borch, RF & Geahlen, RL 2013, 'Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK', Biochemical Pharmacology, vol. 86, no. 5, pp. 597-611. https://doi.org/10.1016/j.bcp.2013.06.024
Huang, Rong ; Oh, Hyunju ; Arrendale, Allison ; Martin, Victoria A. ; Galan, Jacob ; Workman, Eric J. ; Stout, Jane R. ; Walczak, Claire ; Tao, W. Andy ; Borch, Richard F. ; Geahlen, Robert L. / Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK. In: Biochemical Pharmacology. 2013 ; Vol. 86, No. 5. pp. 597-611.
@article{aa792018f3794667a71713ae34407916,
title = "Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK",
abstract = "SH2 domains are attractive targets for chemotherapeutic agents due to their involvement in the formation of protein-protein interactions critical to many signal transduction cascades. Little is known, however, about how synthetic SH2 domain ligands would influence the growth properties of tumor cells or with which intracellular proteins they would interact due to their highly charged nature and enzymatic lability. In this study, a prodrug delivery strategy was used to introduce an enzymatically stable, phosphotyrosine peptidomimetic into tumor cells. When tested in a human tumor cell panel, the prodrug exhibited a preference for inhibiting the growth of leukemia and lymphoma cells. In these cells, it was largely cytostatic and induced endoreduplication and the appearance of midbodies. Proteomic analyses identified multiple targets that included mitotic centromere-associated kinesin (MCAK). Molecular modeling studies suggested the ATP-binding site on MCAK as the likely site of drug interaction. Consistent with this, ATP inhibited the drug-MCAK interaction and the drug inhibited MCAK ATPase activity. Accordingly, the effects of the prodrug on the assembly of the mitotic spindle and alignment of chromosomes were consistent with the identification of MCAK as an important intracellular target.",
keywords = "Drug delivery, Kinesin, MCAK, Peptidomimetic, SH2 domain, Signal transduction",
author = "Rong Huang and Hyunju Oh and Allison Arrendale and Martin, {Victoria A.} and Jacob Galan and Workman, {Eric J.} and Stout, {Jane R.} and Claire Walczak and Tao, {W. Andy} and Borch, {Richard F.} and Geahlen, {Robert L.}",
year = "2013",
doi = "10.1016/j.bcp.2013.06.024",
language = "English",
volume = "86",
pages = "597--611",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK

AU - Huang, Rong

AU - Oh, Hyunju

AU - Arrendale, Allison

AU - Martin, Victoria A.

AU - Galan, Jacob

AU - Workman, Eric J.

AU - Stout, Jane R.

AU - Walczak, Claire

AU - Tao, W. Andy

AU - Borch, Richard F.

AU - Geahlen, Robert L.

PY - 2013

Y1 - 2013

N2 - SH2 domains are attractive targets for chemotherapeutic agents due to their involvement in the formation of protein-protein interactions critical to many signal transduction cascades. Little is known, however, about how synthetic SH2 domain ligands would influence the growth properties of tumor cells or with which intracellular proteins they would interact due to their highly charged nature and enzymatic lability. In this study, a prodrug delivery strategy was used to introduce an enzymatically stable, phosphotyrosine peptidomimetic into tumor cells. When tested in a human tumor cell panel, the prodrug exhibited a preference for inhibiting the growth of leukemia and lymphoma cells. In these cells, it was largely cytostatic and induced endoreduplication and the appearance of midbodies. Proteomic analyses identified multiple targets that included mitotic centromere-associated kinesin (MCAK). Molecular modeling studies suggested the ATP-binding site on MCAK as the likely site of drug interaction. Consistent with this, ATP inhibited the drug-MCAK interaction and the drug inhibited MCAK ATPase activity. Accordingly, the effects of the prodrug on the assembly of the mitotic spindle and alignment of chromosomes were consistent with the identification of MCAK as an important intracellular target.

AB - SH2 domains are attractive targets for chemotherapeutic agents due to their involvement in the formation of protein-protein interactions critical to many signal transduction cascades. Little is known, however, about how synthetic SH2 domain ligands would influence the growth properties of tumor cells or with which intracellular proteins they would interact due to their highly charged nature and enzymatic lability. In this study, a prodrug delivery strategy was used to introduce an enzymatically stable, phosphotyrosine peptidomimetic into tumor cells. When tested in a human tumor cell panel, the prodrug exhibited a preference for inhibiting the growth of leukemia and lymphoma cells. In these cells, it was largely cytostatic and induced endoreduplication and the appearance of midbodies. Proteomic analyses identified multiple targets that included mitotic centromere-associated kinesin (MCAK). Molecular modeling studies suggested the ATP-binding site on MCAK as the likely site of drug interaction. Consistent with this, ATP inhibited the drug-MCAK interaction and the drug inhibited MCAK ATPase activity. Accordingly, the effects of the prodrug on the assembly of the mitotic spindle and alignment of chromosomes were consistent with the identification of MCAK as an important intracellular target.

KW - Drug delivery

KW - Kinesin

KW - MCAK

KW - Peptidomimetic

KW - SH2 domain

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=84884908907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884908907&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2013.06.024

DO - 10.1016/j.bcp.2013.06.024

M3 - Article

C2 - 23830822

AN - SCOPUS:84884908907

VL - 86

SP - 597

EP - 611

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 5

ER -